OpenAI acquires Orchestra Bio to enhance biotech AI capabilities

• OpenAI has acquired Orchestra Bio, a startup specializing in AI for pharmaceutical drug development.
• The acquisition aims to strengthen OpenAI's Rosalind AI model and its Workbench tool for life sciences research.
• Orchestra Bio's team and technology will be integrated into OpenAI's existing biotech initiatives.
• This move reflects the growing trend of AI companies expanding into scientific research.
• OpenAI and other AI giants like Anthropic are increasingly focusing on science beyond their traditional areas of expertise.